3–12 day dispatch window due to updated U.S. documentation requirements • All tariff costs covered
Table of Contents
When comparing botulinum toxin products, the differences can seem subtle at first. For instance, Xeomin and Innotox are both botulinum toxin type A products used to temporarily reduce muscle activity, including in aesthetic medicine, yet they are not simply interchangeable versions of the same treatment. Their formulations, regulatory status, approved indications, handling requirements, and available clinical information can differ depending on the market.
For healthcare specialists, choosing between Xeomin and Innotox is therefore less about finding a universally “better” product and more about understanding the characteristics of each formulation and selecting the option that fits the patient’s needs, the intended indication, and the practitioner’s clinical setting. In this article, we will take a detailed look at the key similarities and differences between the two products.
Before going into detail, here is how the two formulations line up on the characteristics that most often affect a purchasing or treatment decision:
| Characteristic | Xeomin | Innotox |
|---|---|---|
| Manufacturer | Merz Pharmaceuticals (Germany) | Medytox (South Korea) |
| Active ingredient | IncobotulinumtoxinA | Botulinum toxin type A |
| Supplied as | Lyophilised powder, requires reconstitution | Ready-to-use liquid, no reconstitution |
| Complexing proteins | None — the “naked” neurotoxin | None |
| Storage, unopened | At or below 25 °C; refrigeration not required | Refrigerated, 2–8 °C |
| Storage, reconstituted / opened | 2–8 °C, up to 24 hours | 2–8 °C |
| US regulatory status | FDA-approved since 2010 | Not FDA-approved; no US application filed |
| Units interchangeable with other brands | No | No |
Xeomin and Innotox belong to the same broad category of neurotoxin injections. They both are the popular alternatives to Botox treatments and have a similar fundamental therapeutic principle. Namely, botulinum toxin temporarily interferes with neuromuscular transmission, reducing the ability of a targeted muscle to contract. In aesthetic applications, this can soften dynamic wrinkles that develop or become more noticeable as facial muscles repeatedly contract.
Also, both products are therefore used with the aim of achieving a temporary reduction in unwanted muscle activity rather than permanently altering the underlying facial structure. The effect gradually wears off as neuromuscular function returns.
Moreover, both treatments also require appropriate medical assessment during an initial consultation. A patient’s anatomy, muscle activity, medical history, previous botulinum toxin exposure, expectations, and treatment objectives can all influence the suitability of having one or another product injected.
Despite these similarities, however, practitioners should not assume that the products are identical simply because they share the same active ingredient class.
Xeomin is a botulinum toxin type A product manufactured by Merz. One of its distinguishing characteristics is that it contains botulinum toxin without the complexing accessory proteins found in some other botulinum toxin formulations. Thus, Xeomin is often referred to as the naked neurotoxin.
Xeomin is often positioned as a more affordable alternative to Botox. It has been used in both aesthetic and therapeutic medicine, with approved indications varying according to the country and specific product labeling. In aesthetic practice, it is commonly associated with the temporary improvement of certain dynamic facial lines.
The product has an established clinical history, and healthcare professionals can access product-specific prescribing information and clinical data to guide appropriate use. As with any prescription botulinum toxin, practitioners should follow the current official labeling applicable to their market rather than relying on information from another country.
Innotox is another botulinum toxin type A formulation, developed by Medytox, and Innotox is stocked by professional suppliers. It is notable for being presented as a liquid formulation, rather than the conventional freeze-dried powder format used by many botulinum toxin products.
This characteristic can influence how the product is handled in clinical practice. However, the fact that Innotox is supplied as a liquid does not mean that its clinical use can be reduced to a simple preparation advantage. Practitioners still need to follow the manufacturer’s current instructions regarding storage, handling, administration, and approved indications — including the cold chain, which the liquid format does not remove.
The availability and regulatory status of Innotox can also vary between markets. Healthcare professionals should therefore verify that the specific product they are purchasing and using is authorized for their intended application in their jurisdiction.
WORTH KNOWING
Both Botox and other botulinum toxin injections such as Xeomin have passed multiple clinical trials and are approved by the FDA for aesthetic indications. Innotox has clinical trial evidence behind it as well, but it holds Korean MFDS approval rather than FDA approval, so it should not be grouped with the FDA-approved products when describing regulatory status.
According to many patients and their healthcare providers, one of the most interesting differences between Xeomin and Innotox concerns their formulation.
Xeomin is characterized by the absence of complexing proteins. Innotox, meanwhile, is supplied as a ready-to-use liquid formulation. These differences are relevant from a product-handling perspective and help distinguish the two formulations from one another.
However, formulation differences should not automatically be interpreted as proof that one product will produce superior aesthetic results. A product’s clinical performance depends on numerous variables, including the indication, treatment strategy, patient’s anatomy, muscle activity, and practitioner expertise.
For healthcare specialists, formulation should therefore be considered alongside clinical evidence, regulatory information, product availability, storage requirements, and the practical needs of the clinic.
WORTH KNOWING
When comparing Xeomin and Innotox vs. Botox, it is important to remember that all three are botulinum toxin type A products, but they are distinct formulations with their own product information, regulatory approvals, and clinical characteristics. Botox is one of the best-known and most extensively established brands, Xeomin is notable for its purified formulation without complexing proteins, and Innotox is distinguished by its liquid presentation. Their units should not be assumed to be directly interchangeable, and approved indications, handling requirements, and labeling may vary by market.
This is one of the most important questions when comparing the two products, and the answer requires caution.
Although Xeomin and Innotox are both botulinum toxin type A products, their units should not automatically be assumed to be equivalent for clinical decision-making. Botulinum toxin potency units are specific to the individual product and assay system. Consequently, practitioners should not simply take a dose used for one brand and apply it directly to another.
The same principle applies to treatment protocols. A familiar protocol for one botulinum toxin should not automatically become the protocol for another formulation.
When switching between products, practitioners should review the relevant official product information and base treatment decisions on product-specific recommendations, clinical judgment, and the patient’s circumstances.
WORTH KNOWING
The potential to develop neutralizing antibodies is worth considering with repeated neuromodulator injections. Xeomin is formulated without complexing proteins and has been studied specifically in relation to immunogenicity, with clinical evidence generally indicating a low incidence of neutralizing antibodies. Innotox is also free of complexing proteins, but the volume of comparative long-term evidence is smaller. It is therefore not appropriate to assume the two carry identical immunogenicity profiles, nor to claim that either product eliminates the risk of antibody formation. Clinicians should follow product-specific prescribing information and use the lowest effective exposure.
Patients considering Xeomin or Innotox are usually most interested in the visible result: how effectively will the treatment reduce their wrinkles, from tiny forehead lines to severe glabellar lines, and how long will the improvement last? The thing is, there is no single answer that applies equally to every patient. Botulinum toxin effects are temporary, and the duration of the response can vary according to the treatment area, individual muscle activity, the patient’s biology, previous treatments, and other factors.
The quality of the aesthetic result is also strongly influenced by treatment planning. A product cannot compensate for an inadequate understanding of facial anatomy or inappropriate patient selection. Thus, rather than promising an exact duration, practitioners should help patients develop realistic expectations and explain that the effect develops progressively over the first several days and eventually diminishes as normal neuromuscular activity returns. Follow-up allows the clinician to evaluate the patient’s response and document the outcome.
WORTH KNOWING
Onset for both products is usually described in days rather than hours, with visible change over roughly the first three to seven days and the peak effect somewhat later. Most botulinum toxin treatments, Innotox and Xeomin included, are repeated at intervals of around three to four months. Reported figures differ between sources and studies, so the product labelling for the market in question is the reference that matters.
As healthcare providers and their patients describe, both products may be considered as effective aesthetic medicine treatments with natural results when the goal is to reduce the appearance of dynamic facial lines, provided the intended use is consistent with the applicable product labeling.
Common aesthetic concerns associated with botulinum toxin treatments include expression-related lines in areas such as the glabellar region, forehead, and lateral canthal area. The exact approved indications, however, depend on the specific product and jurisdiction.
The choice between Xeomin and Innotox should therefore not be based solely on the name of the treatment area. Practitioners should consider the patient’s facial anatomy and movement pattern, desired degree of correction, previous treatment history, and the characteristics of the particular formulation.
An individualized approach is especially important because excessive weakening of facial muscles can result in an unnatural appearance or unwanted changes in expression. The objective is generally not to eliminate all movement but to achieve an appropriate aesthetic balance.
For many clinics, practical differences can be an important part of the Xeomin versus Innotox discussion — and this is the area where the two genuinely diverge.
Innotox’s liquid presentation removes the reconstitution step and the dilution errors that can come with it. Xeomin still has to be reconstituted, but it carries a storage advantage that is easy to overlook: unopened vials do not need to be refrigerated at all.
“Store unopened vials of XEOMIN at or below 25 °C (77 °F). Refrigeration of unopened vials is not required.” — U.S. Food and Drug Administration, XEOMIN Prescribing Information
Innotox, by contrast, is a cold-chain product and needs refrigeration at 2–8 °C. So the convenience runs in opposite directions: Innotox saves a preparation step at the treatment table, while Xeomin simplifies how stock is stored and transported. Which matters more depends on how a clinic actually operates.
Thus, healthcare specialists should always verify the following peculiarities of injectable neuromodulators:
These details may appear routine, but careful product management is an important part of maintaining quality and patient safety.
Both Xeomin and Innotox are medical products containing botulinum toxin and should be administered only by appropriately qualified healthcare professionals who understand the relevant anatomy, indications, contraindications, and potential complications.
Before treatment, practitioners should review the patient’s medical history and identify factors that could make treatment unsuitable or require additional caution. Relevant considerations can include previous reactions to botulinum toxin, neuromuscular disorders, infection at the proposed treatment area, hypersensitivity, pregnancy or breastfeeding where relevant to the applicable labeling, and certain concomitant medications.
Potential adverse effects may include local discomfort, bruising, swelling, headache, temporary weakness of nearby muscles, asymmetry, and unwanted changes in facial movement. In a small percentage of cases, more widespread effects can occur and require prompt medical evaluation.
Patients should receive appropriate information about expected effects as well as symptoms that should prompt them to contact a healthcare professional.
WORTH KNOWING
Both products are formulated without complexing proteins, and Innotox additionally omits human serum albumin. These characteristics are often described as reducing the theoretical potential for immune response, but neither removes the possibility of adverse reactions, and direct comparative data between the two formulations are limited. Distant spread of toxin effect is a class warning that applies to all botulinum toxin products.
Shortly, there is no universal winner in the Xeomin versus Innotox comparison. For one practitioner, Xeomin may be preferable because of familiarity with the product, its regulatory status in their market, or the available clinical documentation. Another qualified practitioner may find Innotox’s formulation and product characteristics particularly suitable for their clinical workflow.
The most appropriate choice depends on factors such as:
Cost can also influence purchasing decisions for clinics, but price alone should not determine the selection of a prescription medical product. Product authenticity, appropriate storage, regulatory compliance, and reliable sourcing are much more important considerations.
When deciding between Xeomin and Innotox, the best approach is to evaluate the complete clinical context rather than comparing isolated product characteristics.
First, confirm that the intended indication is approved for the particular product in the relevant market. Next, review the current manufacturer information, including contraindications, warnings, storage requirements, and other product-specific instructions. The patient’s individual characteristics should then be considered alongside the practitioner’s experience and the desired treatment outcome.
It is also important to purchase botulinum toxin products through legitimate professional channels. Counterfeit or improperly stored products can present significant risks and may not provide the expected clinical effect.
For a specialist practice, consistency and traceability are valuable as well. Keeping accurate records of the product, batch information, treatment date, and patient response can help clinicians evaluate outcomes over time and make better-informed decisions at subsequent appointments.
To sum up, Xeomin and Innotox share the same broad therapeutic category but have meaningful differences in formulation, presentation, regulatory status, and product-specific information. Xeomin is well established as a botulinum toxin type A formulation without complexing proteins and is FDA-approved, while Innotox stands out for its liquid formulation and holds Korean MFDS approval rather than FDA approval. Neither product can be described as universally superior. Most importantly, Xeomin and Innotox should not be treated as automatically interchangeable simply because both contain botulinum toxin type A.
If you are currently looking for a reliable supplier of Xeomin or Innotox, check out the product selection of FillerCloud! Here, you will find a wide variety of active neurotoxins at advantageous wholesale prices!
No. Botulinum toxin potency units are specific to each product and assay system, so a dose used for one brand cannot be carried over to another. The same applies to injection protocols. When switching between products, review the official product information for the formulation you are actually using and base the dose on that.
It depends which part of the workflow you mean. Innotox arrives as a ready-to-use liquid, so there is no reconstitution and no dilution error at the treatment table. Xeomin has the storage advantage: unopened vials are kept at or below 25 °C and refrigeration is not required, while Innotox needs a 2–8 °C cold chain. Once reconstituted, Xeomin is refrigerated and used within 24 hours.
No. Xeomin has held FDA approval in the United States since 2010. Innotox is approved by South Korea’s Ministry of Food and Drug Safety and is used in a number of markets, but it is not FDA-approved and no US application has been filed. Using a product outside its approved market carries additional considerations around consent, recordkeeping and importation.
Neither does. Both formulations are free of complexing proteins, which is often described as lowering the theoretical immune stimulus, and Xeomin in particular has been studied for immunogenicity with a low reported incidence of neutralising antibodies. But no botulinum toxin removes the risk entirely, and the comparative long-term evidence between these two products is limited. Use the lowest effective dose and the longest practical interval.
You may download the form, complete it and email back to [email protected].
Or fax it at 360.768.3126
